Nektar Therapeutics Stock News

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Mizuho

After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS), Spero Therapeutics (SPRO) and aTyr Pharma

Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN) today and set a price target of $72.00. The company's shares closed last

Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN – Research Report) today and set a price

Mizuho Securities analyst Difei Yang maintained a Buy rating on uniQure (QURE) today and set a price target of $90.00. The company's shares closed last

Mizuho Securities analyst Difei Yang maintained a Buy rating on uniQure (QURE – Research Report) today and set a price